European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLM.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Podrascanin Vanja, Ammann Markus, Gudmundsdottir Hallbera, Dong Yawen, Santol Jonas, Thiels Cornelius A, Warner Susanne G, Truty Mark J, Kendrick Michael L, Smoot Rory L, Fidler Jeff L, Halfdanarson Thorvardur R, Starlinger Patrick P
Аннотация
BACKGROUND: Cytoreductive hepatectomy can offer prolonged survival in patients with neuroendocrine tumor liver metastases (NETLM) but reliable predictors of early mortality, particularly in patients with otherwise similar clinical characteristics, remain unclear. This study aimed to identify preoperative predictors of early mortality following cytoreductive hepatectomy for well-differentiated NETLM.
METHODS: We retrospectively analyzed patients who underwent cytoreductive hepatectomy for well-differentiated NETLM at Mayo Clinic Rochester (2000-2020). Patients were stratified as short-term (<3 years) or long-term (≥3 years) survivors. Preoperative hepatic tumor progression was assessed using RECIST 1.1. Multivariate and subgroup analyses identified predictors of survival.
RESULTS: Among 383 patients, 13 % (n = 51) were short-term and 87 % (n = 332) long-term survivors. Preoperative hepatic progressive disease (PD) per RECIST was significantly more frequent in short-term (47 %) than in long-term survivors (16.6 %, p < 0.001). Patients with pancreatic neuroendocrine tumors (PNET), grade 3 (G3), and RECIST-PD had particularly poor median overall survival (mOS: 1.8 years, p = 0.042). In contrast, among patients with stable disease, survival did not differ by tumor origin (PNET 9.5 years; small bowel neuroendocrine tumors (SBNET) 10 years). Tumor growth >20 % and weekly growth >1.04 % were associated with early mortality (p < 0.001). RECIST-PD (HR: 2.23), larger hepatic metastases (HR: 1.07), and shorter progression-free survival (HR: 1.13) independently predicted worse OS (p < 0.001).
CONCLUSION: Preoperative hepatic tumor progression is the strongest independent predictor of early mortality following hepatectomy for NETLM. In the absence of progression, long-term survival is excellent regardless of tumor origin. These findings support incorporating objective tumor progression metrics into preoperative surgical selection.
METHODS: We retrospectively analyzed patients who underwent cytoreductive hepatectomy for well-differentiated NETLM at Mayo Clinic Rochester (2000-2020). Patients were stratified as short-term (<3 years) or long-term (≥3 years) survivors. Preoperative hepatic tumor progression was assessed using RECIST 1.1. Multivariate and subgroup analyses identified predictors of survival.
RESULTS: Among 383 patients, 13 % (n = 51) were short-term and 87 % (n = 332) long-term survivors. Preoperative hepatic progressive disease (PD) per RECIST was significantly more frequent in short-term (47 %) than in long-term survivors (16.6 %, p < 0.001). Patients with pancreatic neuroendocrine tumors (PNET), grade 3 (G3), and RECIST-PD had particularly poor median overall survival (mOS: 1.8 years, p = 0.042). In contrast, among patients with stable disease, survival did not differ by tumor origin (PNET 9.5 years; small bowel neuroendocrine tumors (SBNET) 10 years). Tumor growth >20 % and weekly growth >1.04 % were associated with early mortality (p < 0.001). RECIST-PD (HR: 2.23), larger hepatic metastases (HR: 1.07), and shorter progression-free survival (HR: 1.13) independently predicted worse OS (p < 0.001).
CONCLUSION: Preoperative hepatic tumor progression is the strongest independent predictor of early mortality following hepatectomy for NETLM. In the absence of progression, long-term survival is excellent regardless of tumor origin. These findings support incorporating objective tumor progression metrics into preoperative surgical selection.